This brochure presents health expenditure data by households, public and private institutions for the 2012/13 fiscal year. The Namibia Health Accounts 2012/13 exercise was undertaken by Government of Namibia with support from the United States Agency for International Development (USAID) Namibia Mis...sion. Program management and support and funding for the health accounts estimation were provided by USAID through the Health Finance and Governance (HFG) project, implemented by Abt Associates Inc. under cooperative agreement AID-OAA-A-12 00080.
more
This summary brief highlights key messages from the updated World Health Organization’s recommendation on tranexamic acid (TXA) for the treatment of postpartum haemorrhage (PPH), including policy and program implications for translating the TXA recommendation into action at the country level. In 2...012, WHO published recommendations for the prevention and treatment of postpartum haemorrhage, including a recommendation on the use of TXA for treatment of PPH. The 2017 updated WHO Recommendation on TXA is based on new evidence on use of TXA for treatment of PPH. This summary brief is intended for policy-makers, programme managers, educators and providers.
more
Guidelines for treatment of drug-susceptible tuberculosis and patient care
2017 update
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
National Tuberculosis and Leprosy Conrol Programme
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
Treating the Patient with Tuberculosis
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...d over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. The disease is endemic in 72 countries. In 2016, an estimated total population of 856 million were living in areas with ongoing transmission of the causative filarial parasites and requiring mass drug administration (MDA). Lymphatic filariasis disfigures and disables, and often leads to stigmatization and poverty. Hundreds of millions of dollars are lost annually due to reduced productivity of affected patients. WHO has ranked the disease as one of the world’s leading causes of permanent and long-term disability.
more
Accessed November 2, 2017